SF 5290
Introduction - 94th Legislature (2025 - 2026)
Posted on 05/14/2026 08:54 a.m.
1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20
1.21 1.22
2.1 2.2 2.3 2.4 2.5 2.6
2.7 2.8
A bill for an act
relating to taxation; individual income and corporate franchise tax; requiring an
addition for certain pharmaceutical marketing expenses; amending Minnesota
Statutes 2024, sections 290.0131, by adding a subdivision; 290.0133, by adding
a subdivision.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
Section 1.
Minnesota Statutes 2024, section 290.0131, is amended by adding a subdivision
to read:
new text begin Subd. 21. new text end
new text begin Pharmaceutical marketing expenses. new text end
new text begin
(a) For the purposes of this subdivision,
the following terms have the meanings given:
new text end
new text begin
(1) "direct-to-consumer pharmaceutical marketing" means advertising, marketing, or
promotional activities directed toward consumers in the United States that are intended to
promote the use, purchase, or prescription of a prescription drug or biologic, including
television, radio, print, digital, and social media advertising, as well as patient-directed
outreach and disease awareness campaigns funded by a pharmaceutical manufacturer and
linked to a specific product; and
new text end
new text begin
(2) "pharmaceutical manufacturer" means a person or entity engaged in the production,
preparation, propagation, compounding, or processing of prescription drugs or biologics.
new text end
new text begin
(b) The amount deducted under section 162 of the Internal Revenue Code for
direct-to-consumer pharmaceutical marketing is an addition.
new text end
new text begin EFFECTIVE DATE. new text end
new text begin
This section is effective for taxable years beginning after December
31, 2026.
new text end
Sec. 2.
Minnesota Statutes 2024, section 290.0133, is amended by adding a subdivision
to read:
new text begin Subd. 16. new text end
new text begin Pharmaceutical marketing expenses. new text end
new text begin
The amount deducted under section
162 of the Internal Revenue Code for direct-to-consumer pharmaceutical marketing is an
addition. For purposes of this subdivision, "direct-to-consumer pharmaceutical marketing"
has the meaning provided in section 290.0131, subdivision 21.
new text end
new text begin EFFECTIVE DATE. new text end
new text begin
This section is effective for taxable years beginning after December
31, 2026.
new text end